Zura Bio Limited announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 ? 3, 2023 in Bangkok, Thailand. The abstracts highlight Zura Bio?s informative research for ZB-168, an anti-IL-7Ra monoclonal antibody with potential across a broad set of indications where the IL-7 or TSLP pathways may be involved, and ZB-880 (torudokimab), a fully human, high affinity monoclonal antibody that neutralizes IL-33 and also has potential for a broad range of indications.

Abstract: WAC23-0180. Title: Biomarker analysis identifies subset of atopic dermatitis patients that respond to IL-33 blockade. Authors:Michael Howell, Ph.D., Jackson Cabell, Brandon Walsh, Ph.D., Someit Sidhu, M.D., Christopher Cabell, M.D. Abstract: WAC23-0179.

Title: ZB-168 potently inhibits thymic stromal lymphopoietin mediated Inflammation. Authors:Christopher Cabell, M.D., Javier Cote-Sierra, Ph.D., Karl Deacon, Ph.D., Someit Sidhu, M.D., Michael Howell, Ph.D.